Your browser doesn't support javascript.
loading
Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
Sayiner, Abdullah; Erdem, Huseyin Aytac; Korkmaz Ekren, Pervin; Tasbakan, Sezai; Basoglu, Ozen K; Tasbakan, Meltem Isikgoz; Yamazhan, Tansu; Gokengin, Deniz; Ozhan, Mustafa Hikmet.
Afiliação
  • Sayiner A; Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey. sayiner2011@gmail.com.
  • Erdem HA; Department of Infectious Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Korkmaz Ekren P; Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Tasbakan S; Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Basoglu OK; Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Tasbakan MI; Department of Infectious Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Yamazhan T; Department of Infectious Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Gokengin D; Department of Infectious Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Ozhan MH; Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
J Infect Dev Ctries ; 16(3): 422-426, 2022 03 31.
Article em En | MEDLINE | ID: mdl-35404846

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article